Aortic Aneurysm

1. Dr. Samatbek Turdaliev

2. Khan Shakira

    Khan Frazia

(1. Teacher, International Medical Faculty, Osh state university, Kyrgyzstan.

2. Students, International Medical Faculty, Osh State University, Kyrgyzstan)

Abstract

Aortic aneurysm is a localized abnormal dilatation of the aorta that tends to progressively enlarge and may eventually rupture. It is generally defined as an increase in aortic diameter of at least fifty percent compared to the expected normal diameter for a given age and sex. Aneurysms are classified based on their location, size, shape, and underlying cause. The condition most commonly involves the abdominal aorta, but it may also affect the thoracic or thoracoabdominal regions.

Introduction

Aortic aneurysm refers to pathologic dilatation of aortic segment that has the tendency to expand and rupture. The extent of dilatation is debatable but one criterion is an increase in the diameter of at least 50% greater than that expected for the same aortic segment in unaffected individuals of same age and sex. Aortic aneurysms are described in terms of their size, location, morphology, and cause.

Epidemiology

The incidence of abdominal aortic aneurysms (AAA) has increased over the past two decades due to population aging, higher smoking rates, improved screening, and better diagnostic methods. AAA is more common in men, with a prevalence of 1.3–8.9% in men compared to 1.0–2.2% in women. Thoracic aortic aneurysms (TAA) occur at an incidence of about 5–10 per 100,000 person-years. Most TAAs involve the ascending aorta (about 60%), followed by the descending aorta (35%) and aortic arch (<10%). Thoracoabdominal aneurysms extend from the descending thoracic aorta into the abdominal aorta.

Key risk factors for AAA include older age, male sex, and smoking. A family history, especially in first-degree male relatives, increases risk about fourfold. Other associated conditions include atherosclerosis, hypertension, hypercholesterolemia, coronary and cerebrovascular disease, and other vascular aneurysms, though some associations are inconsistent. Genetic factors, including variants on chromosome 9p21 (such as rs7025486[A] in the DAB21P gene), also contribute to risk. Black and Asian populations and individuals with diabetes have a lower risk of AAA. TAAs may additionally result from genetic, inflammatory, and infectious causes.

Pathophysiology

· Aortic aneurysmal disease is a degenerative condition affecting all layers of the vessel wall. Its pathophysiology involves four key processes: inflammatory infiltration by lymphocytes and macrophages, breakdown of elastin and collagen by proteolytic enzymes such as matrix metalloproteinases, loss of smooth muscle cells leading to medial thinning, and neovascularization.

· Thoracic aortic aneurysms (TAAs) are strongly influenced by genetic factors, which may present as syndromic conditions or isolated aortic disease. These disorders involve abnormalities in the aortic media, vascular smooth muscle cells, or contractile proteins, often leading to dysregulated signaling pathways. Important associated conditions include Marfan syndrome, Loeys–Dietz syndrome, vascular Ehlers–Danlos syndrome, familial thoracic aortic aneurysm and dissection, bicuspid aortic valve disease, Turner syndrome, and aortopathies linked to congenital heart disease.

Natural History of Aortic Aneurysms

The growth rate of abdominal aortic aneurysms (AAA) measuring 30–55 mm is typically 0.2–0.3 cm per year, with faster expansion seen in larger aneurysms. Thoracic aortic aneurysms (TAA) generally grow more slowly, about 0.1–0.2 cm per year, though this varies individually. Descending aortic aneurysms enlarge faster (≈0.19 cm/year) than ascending ones (≈0.07 cm/year). In the ascending aorta, bicuspid aortic valve (BAV) aneurysms grow faster (≈0.19 cm/year) than those with a tricuspid valve (≈0.13 cm/year).

Rupture risk increases significantly with aneurysm size. For AAAs, rupture risk over 12 months is approximately 0% for 30–39 mm, 1% for 40–49 mm, 1–11% for 50–59 mm, 10–22% for 60–69 mm, and 30–33% for >70 mm. Additional risk factors include female sex, smoking, hypertension, rapid aneurysm expansion, and increased wall stress. Other reported risks include thrombus growth, increased wall stiffness, low FEV1, and post-transplant status.

For TAAs, annual risk of rupture or dissection is about 2% for aneurysms <5 cm, 3% for 5.0–5.9 cm, and 7% for ≥6 cm. Body size and sex also influence risk. The aortic size index (ASI) helps stratify risk: <2.75 cm/m² carries ~4% event rate, 2.75–4.25 cm/m² about 8%, and >4.25 cm/m² up to 20–25% risk.

Screening

Ultrasonography is the main screening tool for abdominal aortic aneurysm (AAA) due to its high sensitivity (about 95%) and specificity (100%). Computed tomography (CT) and magnetic resonance imaging (MRI) are not used for routine screening because of higher cost and risks such as radiation exposure (CT) and contrast-related complications; they are mainly reserved for preoperative planning.

The development of a new AAA after a normal ultrasound at age 65 is rare and usually not clinically significant. Screening is therefore targeted toward high-risk groups. The U.S. Preventive Services Task Force recommends a one-time ultrasound in men aged 65–75 years who have a history of smoking. The Society for Vascular Surgery advises one-time screening for all men over 65, or starting at 55 years in both men and women with a family history of AAA.

Clinical Presentation

1. Unruptured aneurysms

·  Usually asymptomatic and found incidentally on examination or imaging

·  May be detected during screening programs

·  Possible complications:

o   Distal embolization (rare)

o   Acute thrombosis (rare)

·  Non-specific symptoms:

o   Chronic vague abdominal or back pain (due to pressure or organ distension)

o   Sudden severe back/lumbar pain may suggest impending rupture

·  Abdominal aortic aneurysm (AAA) may cause:

o   Ureterohydronephrosis (especially inflammatory or iliac involvement)

·  Thoracic aortic aneurysm (TAA):

o   Often asymptomatic and incidental finding (X-ray, CT, MRI, echo)

o   May present with:

·  Aortic regurgitation

·  Heart failure (aortic root dilation)

·  Embolic events (mural thrombus/atheroma)

·  Mass effect symptoms

2. Ruptured abdominal aortic aneurysm (AAA)

·  Classic triad:

o   Sudden abdominal/flank pain (may radiate to groin/scrotum)

o   Hypotension/shock

o   Pulsatile abdominal mass

·  Severity of shock varies with rupture site and size

·  Types of rupture:

o   Anterolateral rupture → intraperitoneal → often fatal

o   Posterolateral rupture → retroperitoneal → may be temporarily contained

·  Retroperitoneal rupture:

o   Can stabilize briefly (“biphasic course”)

o   Rapid deterioration within hours

·  Rare complications:

o  Contained chronic hematoma

o  Rupture into duodenum

o  Aortocaval fistula:

·  Leg edema

·  High-output heart failure

·  Abdominal bruit

3. Ruptured thoracic aortic aneurysm (TAA)

·  Sudden severe chest or back pain

·  Possible outcomes depending on site:

o  Pleural rupture → hemothorax, hypotension

o  Mediastinal rupture → mediastinal bleeding

o Esophageal rupture → hematemesis (aortoesophageal fistula)

o Tracheobronchial rupture → hemoptysis

·  Infected TAAs more likely to form fistulas

·  Thoracic aortic dissection is more common than rupture

Treatment / Management

Risk factor modification

·       Smoking cessation slows aneurysm growth

·       Control of hypertension and hypercholesterolemia may reduce risk (evidence limited)

·       Regular moderate exercise is safe in small aneurysms and may slow growth

Medical therapy

·  No drug has proven to reliably stop aneurysm progression

·  Studied drugs:

o   Beta-blockers

o   ACE inhibitors / ARBs

o   Statins

o   Antiplatelets

o   Antibiotics and anti-inflammatory agents

·  Doxycycline (MMP inhibitor) showed no significant benefit in trials

·  Overall: medical therapy is supportive, not curative

Indications for aneurysm repair (AAA)

Decision based on balance between rupture risk and surgical risk

Small aneurysms (3.0–3.9 cm):

Very low rupture risk

No surgery required

Regular ultrasound follow-up

Moderate aneurysms (4.0–5.5 cm):

Consider repair if:

Growth >1 cm/year

Symptoms develop

Size thresholds for repair:

≥5.5 cm in males

≥5.2 cm in females (higher rupture risk at smaller size)

Thoracic aortic aneurysm (TAA) repair thresholds

Ascending aorta: surgery at ≥5.5 cm

Bicuspid aortic valve, Marfan syndrome, familial TAA: ≥5.0 cm

Loeys–Dietz syndrome:

o   ~4.2–4.6 cm (or even >4.0 cm in some recommendations)

Turner syndrome:

o   ≥3.5 cm or ≥2.5 cm/m²

Additional factors influencing surgery

Family history of dissection/rupture

Rate of aneurysm growth

Patient sex and body size

Presence of valve disease or need for cardiac surgery

Overall comorbid conditions

Patient and physician preference

Interventions for Aneurysm Repair (EVAR)

Endovascular Aneurysm Repair (EVAR)

Minimally invasive treatment for abdominal aortic aneurysm (AAA)

Involves insertion of a stent graft via femoral artery access

Excludes aneurysm sac from circulation

Requires suitable aortic and iliac anatomy for fixation and sealing

Advantages of EVAR

Shorter operative time

Can be done without general anesthesia

Less surgical trauma and postoperative pain

Shorter hospital stay and reduced ICU need

Lower blood loss

Reduced early postoperative mortality

Disadvantages / complications

Risk of incomplete sealing of aneurysm sac

Endoleaks:

o   Type I: leakage at graft ends

o   Type II: backflow from branch vessels

o   Type III: graft component separation or defect

Morphological requirements (key points)

Adequate proximal aortic neck:

o   Diameter 17–32 mm

o   Length >10 mm

o   Limited thrombus (<50%) and calcification (<50%)

o   Mild angulation (<60°–90° depending on segment)

Suitable iliac arteries:

o   Diameter >7 mm

o   Limited calcification

o   Adequate length (>15 mm)

Aortic bifurcation >20 mm for bifurcated graft

Graft selection

Based on individual anatomy

Graft is usually oversized by 15–20% compared to aortic neck diameter

Oversizing ensures proper sealing and fixation

Management of iliac aneurysms

Present in up to 40% of EVAR patients

Internal iliac (hypogastric) artery often embolized with coils

Endograft extended into external iliac artery

Done to reduce risk of Type II endoleak

Prefer proximal coil placement to preserve collateral flow

Possible complications of hypogastric occlusion:

Buttock claudication (~80% of symptomatic cases)

Erectile dysfunction (~10%)

Colonic ischemia (6–9%)

Outcomes

30-day mortality ~1%

Hospital stay ~3 days

Recovery within days to weeks

Complications of Endovascular Aneurysm Repair (TEVAR/EVAR)

1. Vascular complications

Mainly due to large delivery sheath size

Risk increased in:

o   Small iliac arteries

o   Tortuous vessels

o   Calcified arteries

o   Can lead to access site injury or bleeding

Use of arterial conduits may:

o   Bypass difficult anatomy

o   Improve access

o   Reduce complication rates

2. Neurological complications

Caused by embolization or impaired blood flow

Possible outcomes:

o   Stroke (cerebral embolization)

o   Spinal cord ischemia

Higher risk when:

Hypogastric artery is covered

Left subclavian artery is involved

Extensive thoracic aortic coverage is performed

Presence of:

Renal insufficiency

Intraoperative hypotension (SBP < 80 mmHg)

Prevention:

Careful device manipulation

Proper anatomical planning

Optimal graft positioning

3. Endoleaks

Common complication of TEVAR/EVAR

Defined as persistent blood flow into aneurysm sac after repair

Reported incidence varies widely:

o   ~26% in some trials

o   ~3–4% in others

Risk decreasing with newer generation devices

Conclusion

Aortic aneurysmal disease is a progressive and potentially life-threatening condition resulting from complex degenerative and inflammatory changes in the aortic wall, influenced by both genetic and acquired risk factors. Abdominal aortic aneurysms are more common and strongly associated with aging, male sex, and smoking, while thoracic aneurysms are more often linked to genetic syndromes and connective tissue disorders.

Most aneurysms remain clinically silent until detected incidentally or through screening; however, their natural history is characterized by gradual expansion with an increasing risk of rupture as size increases. Once rupture occurs, mortality is extremely high, particularly in abdominal aneurysms, making early detection and timely intervention critical.

Management is based on careful surveillance, risk factor modification, and selective surgical repair. While medical therapies have not shown clear effectiveness in halting aneurysm progression, lifestyle changes such as smoking cessation and blood pressure control remain important. The decision for intervention depends primarily on aneurysm size, growth rate, symptoms, and patient-specific risk factors.

Endovascular techniques such as EVAR and TEVAR have revolutionized treatment by offering less invasive alternatives to open surgery, significantly reducing perioperative morbidity and mortality. However, they require lifelong surveillance due to complications such as endoleaks, vascular injury, and neurologic events.

Overall, successful management of aortic aneurysms relies on early detection, individualized risk assessment, and a multidisciplinary approach combining surveillance, medical optimization, and timely surgical or endovascular intervention.

References

1. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS. et al. The aneurysm detection and management study screening program: validation cohort and final results. Arch Intern Med. 2000;160:1425–30. doi: 10.1001/archinte.160.10.1425. [DOI] [PubMed] [Google Scholar]

2. Kuzmik GA, Sang AX, Elefteriades JA. Natural history of thoracic aortic aneurysms. J Vasc Surg. 2012;56:565. doi: 10.1016/j.jvs.2012.04.053. [DOI] [PubMed] [Google Scholar]

3. Johansen K, Koepsell T. Familial tendency for abdominal aortic aneurysms. JAMA. 1986;256:1934–6. [PubMed] [Google Scholar]

4. Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D. et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997;126:441–9. doi: 10.7326/0003-4819-126-6-199703150-00004. [DOI] [PubMed] [Google Scholar]

5. Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A. et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217–24. doi: 10.1038/ng.72. [DOI] [PubMed] [Google Scholar]

6. Ailawadi G, Eliason JL, Upchurch GR Jr. Current concepts in the pathogenesis of abdominal aortic aneurysm. J Vasc Surg. 2003;38:584–8. doi: 10.1016/s0741-5214(03)00324-0. [DOI] [PubMed] [Google Scholar]

7. Doyle JJ, Gerber EE, Dietz HC. Matrix-dependent perturbation of TGF beta signaling and disease. FEBS Lett. 2012;586:2003–15. doi: 10.1016/j.febslet.2012.05.027. [DOI] [PMC free article] [PubMed] [Google Scholar]

8. Davies RR, Gallo A, Coady MA, Tellides G, Botta DM, Burke B. et al. Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg. 2006;81:169–77. doi: 10.1016/j.athoracsur.2005.06.026. [DOI] [PubMed] [Google Scholar]

9. Braverman AC. The Bicuspid Aortic Valve and Associated Aortic Disease in Valvular Heart Disease: A Companion to Braunwald’s Heart Disease. Philadelphia: Saunders/Elsevier; 2013. [Google Scholar]

10. Conway KP, Byrne J, Townsend M, Lane IF. Prognosis of patients turned down for conventional abdominal aortic aneurysm repair in the endovascular and sonographic era: Szilagyi revisited? J Vas. Surg. 2001;33:752–7. doi: 10.1067/mva.2001.112800. [DOI] [PubMed] [Google Scholar]

11. Lindholt JS, Ashton HA, Scott RA. Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms. J Vasc Surg. 2001;34:212–5. doi: 10.1067/mva.2001.115816. [DOI] [PubMed] [Google Scholar]

12. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr. et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121:e266–369. doi: 10.1161/CIR.0b013e3181d4739e. [DOI] [PubMed] [Google Scholar]

Previous
Previous

Awareness and Understanding of Cerebral Palsy Among the General Population: A Cross-Sectional Survey

Next
Next

Combined Valvular Heart Disease: A Comprehensive Clinical Review Of Etiology, Diagnosis